- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | 12 | Investing.com | ||
| Mi | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | 1 | Investing.com | ||
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| 23.01. | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | 5 | Investing.com Deutsch | ||
| 23.01. | Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock | 3 | Investing.com | ||
| 15.01. | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | 16 | Insider Monkey | ||
| 13.01. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | 256 | GlobeNewswire (Europe) | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| 12.01. | Praxis Precision Medicines plans two NDA submissions by mid-February | 9 | Investing.com | ||
| 12.01. | Praxis Precision Medicines plant zwei Zulassungsanträge bis Mitte Februar 2026 | 6 | Investing.com Deutsch | ||
| 09.01. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 08.01. | Praxis Precision Medicines appoints new board members, promotes executives | 1 | Investing.com | ||
| 08.01. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | 429 | GlobeNewswire (Europe) | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| 07.01. | Praxis Precision Prices $575 Mln Public Offering At $260/shr | 1 | RTTNews | ||
| 07.01. | Praxis Precision prices $575M stock offering at $260 | 2 | Seeking Alpha | ||
| 07.01. | Praxis Precision Medicines prices public offering at $260 per share | 3 | Investing.com | ||
| 07.01. | Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering | 3 | GlobeNewswire (USA) | ||
| 06.01. | Praxis Precision Medicines meldet vorläufige Liquidität von 925 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 06.01. | Praxis Precision Medicines announces proposed public offering | 2 | Investing.com | ||
| 06.01. | Praxis Precision Medicines: Aktie gibt nach Ankündigung einer Kapitalerhöhung nach | 2 | Investing.com Deutsch | ||
| 06.01. | Praxis Precision Medicines kündigt öffentliches Aktienangebot an | 1 | Investing.com Deutsch | ||
| 06.01. | Praxis Precision Medicines announces proposed public stock offering | 1 | Seeking Alpha |
1 2 3 4 5 Weiter >>
115 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,460 | +9,49 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| QIAGEN | 44,035 | -0,06 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| MODERNA | 35,690 | -1,14 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| AMGEN | 288,35 | -1,39 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| NOVAVAX | 6,980 | -5,23 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 151,55 | -0,20 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| ILLUMINA | 115,00 | -3,91 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,800 | +0,46 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,440 | 0,00 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OCUGEN | 1,275 | +5,46 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,935 | -1,09 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,590 | -2,45 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| EDITAS MEDICINE | 1,680 | -1,73 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,682 | +1,10 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,190 | +0,08 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen |
Das Unternehmen PRAXIS PRECISION MEDICINES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,29 % bei einem Aktienkurs von 310,02 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRAXIS PRECISION MEDICINES INC finden Sie auf Wallstreet Online.